MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663175] 05425719  
CLINICAL STUDY PROTOCOL  
A Pi[INVESTIGATOR_22735], Open Label, Multi -Center, Safety and Pharmacokinetic Study of MB-102 
(Relmapi[INVESTIGATOR_512481] ) and the Use of the MediBeacon® Transdermal GFR Measurement System 
in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function  
 
 
Statement of Compliance  
The study will be conducted  in compliance with the protocol, International Conference on Harmonization Good 
Clinical Practice E6  R2 (ICH -GCP), and the applicable regulatory requirements including  the National Medical 
Products Administration Good Clinical Practice (NMPA GCP) , The Code of Federal Regulations Title 21 CF R Parts 
812, 11, 50, 54 and 56 and ISO [ZIP_CODE]: 2 020 (3rd Edition)  Clinical Investigation of Medical Devices for Human 
Subjects – Good Clinical Practice  
 Protocol Number:  100-[ADDRESS_663176]:  MB-102 (Relmapi[INVESTIGATOR_512481])  / MediBeacon® Transdermal GFR 
Measurement System  
Phase:  Pi[INVESTIGATOR_38086]:  MediBeacon Inc.  
[ADDRESS_663177]. Louis, MO 631 41 
[LOCATION_003]  
 
Date of Protoco l 20 September  2022  
Version of Protocol:  Version 4.[ADDRESS_663178] party without the 
written permission of MediBeacon Inc.  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 2 of 57 
 1 Synopsis  
Protocol Number:  100-003 
Title:  A Pi[INVESTIGATOR_22735] , Open Label, Multi -Center,  Safety and Pharmacokinetic Study of MB-
102 ( Relmapi[INVESTIGATOR_512481] ) and the Use of the MediBeacon® Transdermal GFR 
Measurement System  in Normal and Renal Compromised Subjects for the 
Evaluation of Kidney Function  
Investigational 
Product s: MB-102 ( Relmapi[INVESTIGATOR_512481] ) 
MediBeacon® Transdermal GFR Measurement System  (TGFR)  
Number of Study 
Sites:  This study will take place at up to 10 investigational sites in the US  and China  
Phase:  Pi[INVESTIGATOR_512482] s: • To establish  that the MB-102 transdermal fluorescence measured GFR 
using the MediBeacon® Transdermal GFR Measurement System is 
comparable  to the measured MB-102 plasma GFR   
• To evaluate the safety and tolerability of a single dos e of MB-102 in 
subjects   
• To evaluate the safety and effectiveness of the MediBeacon® Transdermal 
GFR Measurement System  for the non -invasive transdermal fluorescence 
detection of MB-102 in subjects  
Study Design:  Multi -center, p ivotal open -label pharmacokinetic study  comparing transdermal 
measured GFR ( tGFR ) to plasma -derived indexed GFR (nGFR).  
Number of Treated 
Subjects:  Up to [ADDRESS_663179] 140 evaluable subjects; Chinese  sites will plan to enroll at least  48 
evaluable subjects.  The population will be split into stratums  in accordance with 
screening eGFR measured by [CONTACT_91019] -EPI [INVESTIGATOR_10908]:  
• Stratum  1: 50% of  evaluable  subjects with  an eGFR ≥ 70 mL/min /1.73 m2 
• Stratum  2: 50% of  evaluable  subjects with  an eGFR < 70 mL/min /1.73 m2 
Approximately 50% of subjects  within each Stratum enrolled in the US  will be 
Fitzpatrick skin scale  (FSS)  I-III and 50% of subjects will have FSS IV-VI. 
Subjects in the US will be enrolled across a spectrum of both eGFR (<120 - >15  
mL/min /1.73 m2) and FSS.  
 
Subjects enrolled in China will also be represented across the same spectrum of 
eGFR (<120 - >15 mL/min /1.73 m2) however the FSS will not apply. This is 
because  the Chinese  subject demographic is unlikely to represent the full FSS  
spectrum .  
Subjects with incomplete assessments or major protocol deviations may be 
replaced. Thus,  a maximum of 2 50 subjects may be enrolled.  
Treatment:  Eligible subjects  in stratums 1  and 2 will receive a single 130 mg  dose of MB-
102.  
Blood draws will be taken at pre -defined timepoints and the MediBeacon® 
Transdermal GFR Measurement System  fluorescent measurements will be 
collected over a  12 hour  - 24 hour period . 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663180]:  Screening period: up to 21 days prior to dosing; dosing day, and a follow -up visit 
within 7+/ -3 days of dosing.   
Study Population:  Main Criteria for Inclusion:  
1. Age > 18 years – male or female  
a. Eligible female non-pregnant subjects who are either not of 
child -bearing potential or willing to use adequate 
contraception during the trial  
b. Males must be willing to practice abstinence or utilize 
adequate contraception from dosing day to at least [ADDRESS_663181] at screening, and agrees 
to one of the following acceptable contraceptive methods 
used consistently and correctly i.e. abstinence, oral 
contraceptive either combined or progesterone alone; 
injectable  progesterone, implants of levonorgestrel, 
estrogenic vaginal ring, percutaneous contraceptive patches, 
IUD device or system or male partner sterilization  
d. Men will not donate sperm during the study and for [ADDRESS_663182] dose of study drug  
2. Subjects who are capable of directly providing informed consent and 
who can comply with the requirements and restrictions required by 
[CONTACT_760]  
3. Adequate venous access sufficient to allow blood sampling per 
protocol requirements  
Main Criteria for Exclusion:  
1. Subjects positive via PCR testing for COVID -19 
a. Vaccinated subjects without symptoms of COVID -19 are not 
required to undergo PCR testing but may be tested at the 
discretion of the study site 
2. Recent donation or loss of blood or plasma: 100 mL to 499 mL 
within 30 days prior to the initial dose of the study medication; or 
more than 499 mL within 56 days prior to the initial dose of study 
medication  
3. Non-steroidal anti -inflammatory (NSAID) use within [ADDRESS_663183] within the following time ranges: prior to the 
first dosing day in the current study :  either  [ADDRESS_663184] (whichever duration is longer).  
5. History of skin sensitivity to adhesives (e.g. Band -Aids, surgical 
tape)  
6. History of severe allergic hypersensitivity reactions (unacceptable 
adverse events) or anaphylactoid reaction to any allergen including 
drugs, MB -102 or other related products (intolerance to a drug is not 
considered a drug allergy).  
7.  Any characteristics such as acute or chronic medical condition or 
cardiac or laboratory or physical examination abnormality that may 
increase the risk associated with study participation or investigational 
product administration or may interfere with the interpretation of the 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663185] inappropriate for entry into this study.  
8. Significant scaring, tattoos or alterations in pi[INVESTIGATOR_512483]  
9. Any serious or uncontrolled medical disorder, active infection, 
physical exam finding, laboratory finding, or psychiatric condition 
that in the opi[INVESTIGATOR_512484]’ ability 
to complete study requirements or may put the subj ect at increased 
risk or compromise the interpretability of study results.  
10. Currently receiving dialysis  
11. Currently anuric  
12. Subject s with positive serum pregnancy test  
13. Subjects with an eGFR > 120 mL/min/1.73m2 
 
Primary Endpoint:  The primary endpoint is the performance measure of P30 for transdermal -
derived GFR with respect to the plasma -derived indexed GFR, with a 95% 
confidence interval. The performance goal is 85%. Success for the study will be 
that the lower limit of the 95% CI is greater than 85%.  
Safety Evaluation  • Safety of MB-102 will be evaluated through treatment emergent adverse 
events (TEAEs), where treatment emergence is defined with respect to the 
first administration of MB-102. 
• Safety of the MediBeacon® Transdermal GFR Measurement System will be 
evaluated through TEAEs, where treatment emergence is defined with respect 
to the start time of device use . 
Statistical Analyses   The primary endpoint is the performance measure of P30 for transdermal -
derived GFR with respect to the plasma -derived indexed GFR, with a 95% 
confidence interval. The performance goal is 85%. Success for the study will be 
that the lower limit of the 95% CI is greater than 85%.  
 
Safety of MB -102 will be evaluated through treatment emergent adverse events 
(TEAEs), where treatment emergence is defined with respect to the 
administration of MB -102. 
 
Safety of the MediBeacon® Transdermal GFR Measurement System will be 
evaluated through TEAEs, where treatment emergence is defined with respect 
to the start time of Transdermal GFR Measurement System use.  
 
Additional safety variables include physical examinations, vital sign 
measurements, ECGs, clinical laboratory assessments, and medication use.  
Sample Size 
Determination  For a P30 true value of 0.95, alpha of 0.025, performance goal of 85%, power 
of 90%, the one -sided exact binomial test yields a sample size of 102. 
 
Time Schedule:  Planned Start of Study:  Q2 2022  
Planned End of Study:   Q4 2022 
 
  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663186] Dorshow, PhD      Date  
President & Chief Scientific Officer  
 
 
 
 
____________________________________   _________  
Joseph Pi[INVESTIGATOR_360101], MD       Date  
Acting Head: Medical Affairs  
 
 
 
 
____________________________________   _________  
Nancy Morrison       Date  
Acting Head: Regulatory Affairs  
 
 
 
 
____________________________________   _________  
Elizabeth LaPointe, MA      Date  
Acting Head: Clinical Operations  
 
 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663187] of Abbreviations and Definition of Terms  ................................ ................................ .... 9 
3 Introduction  ................................ ................................ ................................ ................................ .. 11 
3.1 Background  ................................ ................................ ................................ ...........................  11 
3.2 Nonclinical Data  ................................ ................................ ................................ ...................  12 
3.3 Clinical Data  ................................ ................................ ................................ ..........................  12 
3.4 Study Rationale  ................................ ................................ ................................ ....................  13 
4 Study Objectives  ................................ ................................ ................................ ..........................  13 
5 Investigational Plan ................................ ................................ ................................ ....................  14 
5.1 Overall Study Design and Plan ................................ ................................ ........................  14 
5.2 Overview of Study Procedures  ................................ ................................ .......................  14 
5.3 Discussion of Study Design  ................................ ................................ ..............................  15 
5.4 Selection of Study Population  ................................ ................................ .........................  15 
5.4.1  Number of Planned Evaluable Subjects  ................................ ................................ ..........  15 
5.4.2  Inclusion Criteria  ................................ ................................ ................................ .....................  16 
5.4.3  Exclusion Criteria  ................................ ................................ ................................ .....................  16 
5.4.4  Removal of Subjects from Therapy or Assessments  ................................ ..................  17 
5.4.5  Replacement of Subjects  ................................ ................................ ................................ ....... 17 
5.5 Investigational Device  ................................ ................................ ................................ ....... 18 
5.5.1  Premature Dislodgment of a TGFR Sensor from the Skin  ................................ ........  18 
5.5.2  Sensor Detachment from the TGFR Monitor  ................................ ................................ . 18 
5.5.3  Identity of Investigational Device  ................................ ................................ ......................  18 
5.5.4  Labeling  ................................ ................................ ................................ ................................ ....... 19 
5.5.5  Storage, Supply and Return/Destruction  ................................ ................................ ....... [ADDRESS_663188]  ................................ ................................ ................................ ...... 20 
5.6.2  Identity of Investigational Drug  ................................ ................................ .........................  21 
5.6.3  Investigational Drug Labeling  ................................ ................................ .............................  21 
5.6.4  Investigational Drug Storage, Supply, Return/Destruction  ................................ .... [ADDRESS_663189] Procedures for Medical Issues Requiring Immediate Attention  ........  22 
5.8 Prior and Concomitant Therapy  ................................ ................................ ....................  23 
5.8.1  Prohibited Concomitant Medications  ................................ ................................ ..............  23 
5.8.2  Stable Use of Immunosuppressive Medications  ................................ ..........................  23 
6 Study Procedures  ................................ ................................ ................................ ........................  23 
6.1 Schedule of Assessments and Procedures  ................................ ................................ .. 24 
6.2 Pre-screening  ................................ ................................ ................................ .......................  27 
6.3 Screening  ................................ ................................ ................................ ................................  27 
6.4 Night before Dosing Day  ................................ ................................ ................................ ... 27 
6.5 Dosing Day: Baseline Assessments  ................................ ................................ ...............  28 
6.6 MB-102 Dosing  ................................ ................................ ................................ .....................  29 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663190] -dose Study Procedures  ................................ ................................ ............................  30 
6.7.1  Stratum 1 (12 hour follow -up) ................................ ................................ ...........................  30 
6.8 Stratum 2 (24 hour follow -up) ................................ ................................ .......................  31 
6.9 Follow -up Visit  ................................ ................................ ................................ .....................  32 
6.10  Early Withdrawal / Unscheduled Visits  ................................ ................................ .. 32 
6.11  Repeat Subjects  ................................ ................................ ................................ ................  33 
7 Efficacy and Safety Variables  ................................ ................................ ................................ .. 33 
7.1 Efficacy and Safety Measurements Assessed and Flow Chart  ..............................  33 
7.1.1  Efficacy Assessments  ................................ ................................ ................................ ..............  33 
7.1.2  Safety Assessments  ................................ ................................ ................................ .................  33 
7.2 Safety Review Committee  ................................ ................................ ................................ . 40 
8 Information for the Investigator: Potential Risks of the Device  ................................ . 41 
8.1 Investigational Drug  ................................ ................................ ................................ ...........  41 
8.2 MediBeacon® Transdermal GFR Measurement System  ................................ ........  [ADDRESS_663191] Disposition  ................................ ................................ ................................ .............  43 
9.4 Plasma Pharmacokinetic Analyses  ................................ ................................ ...............  43 
9.5 Primary Endpoint Analysis  ................................ ................................ ..............................  44 
9.6 Safety Analyses  ................................ ................................ ................................ .....................  44 
9.6.1  Treatment -Emergent Adverse Events  ................................ ................................ .............  45 
9.6.2  Physical Examinations/Limited Physical Assessments  ................................ ............  [ADDRESS_663192] Data Collection  ................................ ................................ ................................ .... 48 
11 Records / Retention  ................................ ................................ ................................ ...............  48 
12 Ethics  ................................ ................................ ................................ ................................ ...........  49 
12.1  Independent Ethics Committee (IEC)  ................................ ................................ ....... [ADDRESS_663193] of the Study  ................................ ................................ ........................  50 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663194] Confidentiality  ................................ ................................ ................................ .. 50 
12.6  Reporting and Publication, Including Archiving  ................................ ..................  51 
13 References  ................................ ................................ ................................ ................................ . 52 
14 Appendix A Fitzpatrick Scale  ................................ ................................ ..............................  53 
15 Appendix B Clinical Research Sites  ................................ ................................ ...................  54 
Investigator Signature [CONTACT_3490]  ................................ ................................ ................................ ............  55 
16 Signature [CONTACT_19618]’s Responsible Officers  ................................ ..........................  56 
16.1  Chief Scientific Officer  ................................ ................................ ................................ ... 56 
16.2  Medical Officer  ................................ ................................ ................................ .................  56 
Appendix I  Protocol 100 -003 Supplemental Justifications  ................................ .................  57 
 
  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663195]  Aspartate aminotransferase  
BMI  Body Mass Index  
BP Blood pressure  
BUN  Blood urea nitrogen  
CFR  Code of Federal Regulations  
CKD  Chronic kidney disease  
CKD -EPI [INVESTIGATOR_512485] – epi[INVESTIGATOR_512486] [ADDRESS_663196]  Hematocrit  
HEENT  Head, Ears, Eyes, Neck, Throat  
I Iodine  
IB Investigator ’s Brochure  
ICF informed Consent Form 
ICH International Council on Harmoni sation  
ICU Intensive Care Unit  
IDE Investigational Device Exemption  
IEC Independent Ethics Committee  
INR International normalized ratio  
IP Investigational Product  
ISO International Organization for Standardization  
K Potassium  
K2EDTA  Potassium ethylenediaminetetraacetic acid  
MedDRA  Medical Dictionary for Regulatory Activities  
nGFR  
NIH Indexed plasma glomerular filtration rate  
National Institute of Health  
NSAID  Non-steroidal anti -inflammatory drug  
OM Operational Manual  
ORFM  Optical Renal Function Monitor  
OTC  Over the counter  
PA Physical Assessment (limited)  
PE Physical exam (full)  
PI [INVESTIGATOR_41805] I nvestigator  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 10 of 57 
 PK Pharmacokinetic  
POC  Point of care  
PP Per Protocol  
RBC  Red blood cell  
SAE  Serious Adverse Event 
SAF Safety Analysis Set  
SAP Statistical Analysis Plan  
SCr Serum creatinine  
SNR  Signal to Noise Ratio  
Tc-DTPA  Technetium diethylene triamine - pentaacetate  
TEAE  Treatment -emergent adverse event  
tGFR  Transdermal Glomerular Filtration Rate  
TGFR  
UADE  MediBeacon® Transdermal GFR Measurement System  
Unanticipated Adverse Device Effect  
Vd Volume of Distribution  
WBC  White blood cell  
WHO World Health Organization  
WOCBP  Women of Child -Bearing Potential  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 11 of 57 
 3 Introduction  
3.1 Background  
Therapeutic interventions for acute kidney injury (AKI) patients are delayed due to current 
clinical practice of reliance on a serum creatinine blood test (SCr) for an estimation of 
glom erular filtration rate ( GFR ). Typi[INVESTIGATOR_897] , 24-72 hours elapse from onset of a kidney injury 
event to a SC r indicating a non -normal level  (Stevens et al, 2006) . Since AKI affects upwards of 
20% of hospi[INVESTIGATOR_2764] 70% of critically ill patients in the intensive care unit (ICU), 
this contributes  to high mortality rates (approaching 60% for those requiring renal replacement 
therapy  [Endre at al., 2011] ), development of chronic kidney disease (affecting an estimated 27 
million Americans, accounting for ~ 24% of Medicare costs  [NIH 2008] ), and consequent 
progression to end stage renal disease (with an estimated 400,000 Americans on dialysis  [Kidney 
Disease Statistics for the US] ). 
 
Glomerular filtration rate (GFR) is widely accepted as the best indicator of kidney function and 
is a key component of the diagnosis  and management of renal impairment.  A simple, accurate, 
and point -of-care (POC) method for determining GFR is needed, as current methods for 
determining GFR are either: 1) practical but lack accuracy, or 2) accurate but prohibitively 
complex, especially for frequent and recurrent measurement s. 
 
Current medical practice for general renal function assessment relies on estimated GFR 
(eGFR).  This involves estimation using equations based on a single serum creatinine (SCr) 
measurement, or a measurement of  creatinine clearance (CrC l) based on a 24 -hour collection 
of urine plus measurement of a single SCr concentration .  Although readily available and 
convenient, measurement of SCr as an indicator of renal function is problematic because it is a 
lagging indicator of current renal function, lacks sensiti vity, and may be misleading because it 
is affected by [CONTACT_654], state of hydration, renal perfusion, muscle mass, dietary intake, and many 
other anthropometric and clinical variables  (Agarwal, [ADDRESS_663197] et al., 2005) .  CrCl  
estimation using timed urine collections can be more accurate, but problems with 
completeness of [ADDRESS_663198] three decades, renally filtered 
exogenous agents such as inulin, iohexol, 125Iodine -iothalamate  (125I-iothalamate ), and 
technetium -99m-diethylene triamine - pentaacetate  (99mTc-DTPA ) have all been used to 
determine GFR  (Stevens et al., 2006) .  From both a safety and effectiveness standpoint, these 
agents are acceptable, although they contain iodine, which c an cause anaphylactoid reactions, 
and they can be nephrotoxic when very high volumes are used.  However, they are not used 
routinely to determine GFR because the protocols are time -consuming, complex, and expensive, 
which make their repeated use  impractical in many clinical settings, and they may require 
imaging equipment and administration of radioactive agents ( Stevens and Levey, 2009).   
Accurate measurement of GFR at the patient’s bedside is highly desirable in order to assess the 
patient’s renal  functio n.  There is a significant need to develop a simple, accurate, and POC 
method for measuring GFR  (Erley et al., 2001) . 
 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663199] that 
requires the administration of a fluorescent tracer agent designated relmapi[INVESTIGATOR_512481]  (also known as 
MB-102 and formerly known as  MP-3180) that will be detected transdermally by a sensor which 
is attached to a device monitor  (called t he MediBeacon® Transdermal GFR Measurement System  
[TGFR]) .   
 
MB-102 has been engineered to be excreted from the body by [CONTACT_239585], and specifically 
by [CONTACT_512512]. Normal functioning kidneys will remove this agent from the body with 
an approximate 2 hour half-life. Impaired functioning kidneys will take long er to excrete the 
agent and hence result in a longer half -life.  
 
An initial algorithm had been developed from the Pi[INVESTIGATOR_2268] 2 study Group 1 data to convert measured 
fluorescence half -life data to GFR. Pi[INVESTIGATOR_2268] 2 study Groups 2 and 3 refined this algorithm for 
efficacy and robustness, as well as adding to the algorithm database . 
 
The sensor contains the light source for excitation of the tracer agent , the agent having a peak 
absorption wavelength of 440 nm . The detector is able to acquire the emission of the tracer 
agent, the agent having a peak emission wavelength of 560 nm. The sensor for the TGFR device 
is small  and limited to the materials necessary for excitation and acquisition, and collection and 
processing of the data is conducted within the monitor .  The device monitor displays the TGFR 
data.    
 
3.2 Nonc linical Data  
Available  nonclinical study data  on MB-102 support that the chemistry of the drug 
substance/drug product, and the manufacturing of the drug substance/drug product  does not 
present a risk to human subjects . Additional information on the 24 nonclinical studies performed 
on MB -102 is found in the Investigator’s Brochure.  
 
3.[ADDRESS_663200] been treated with  an IV administration of  MB-102 across the three 
pi[INVESTIGATOR_7602] (Pi[INVESTIGATOR_2268] 1 A, Pi[INVESTIGATOR_2268] 1 B and Pi[INVESTIGATOR_2268] 2 Group s 1, 2 and 3 ). The Pi[INVESTIGATOR_2268] 1 studies enrolled 
subjects with an eGFR indicating normal renal function. The Pi[INVESTIGATOR_2268] 2 study enrolled subjects with 
normal renal function and those with renal function in the CKD stage 1 -5 range. In addition, a 
total of 22 subjects ( 11 healthy volunteers and 11 Crohn’s patients) have received a 4 or 8 
µmol/kg  oral dose of MB -102 in a study evaluating the use of MB -102 in the evaluation of gut 
permeability (MediBeacon Protocol 300 -01). The total population exposure to MB -102 as of this 
protocol  is 288 subjects. A total of 52 subjects ( 18.1% of the total population across 4 studies ) 
were reported to have adverse events  (AE) . All reported events were mild or moderate in 
severity. No severe events have been reported, nor have any serious adverse events been reported  
or unanticipated adverse device effects . 
 
There have been no clinically significant findings with regard to vital signs, physical exams or 
ECGs.   Overall MB -102 administered intravenously at a dose of 4 µmol/kg whether or not 
followed by a 5 mL (milliliter) dose of iohexol (Omnipaque ™ 300), or at a fixed dose of 130 mg 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 13 of 57 
 / 7 mL ( n=44 ) or consumed orally at a dose of 4 µmol/kg  (n=8)  or 8 µmol/kg  (n=1 4) was well 
tolerated in the populations studied to date . 
 
Adverse events related to the device itself were due to the adhesive materials used to hold the 
ORFM  (Optical Renal Function Monitor)  sensor in place.  All device related events were 
considered mild  or moderate  in severity. For more information, please see the Investigator’s 
Brochure.  
 
MB-[ADDRESS_663201] administration; in Pi[INVESTIGATOR_2268] 1B 
the first sample time point taken was approximately [ADDRESS_663202].  MB-102 
concentration equilibration between the vasculature and the tissue occurs approximately 30 – [ADDRESS_663203] using the prototype device 
QuantumLeap and Radiance. For all 120 subjects over the wide range of GFR values, th e 
following were observed:  
 
• A two-compartment plasma pharmacokinetic profile  
• A high correlation between the MB-102 and iohexol plasma derived GFR values  
• A high correlation between the MB-102 plasma and transdermal fluorescence 
pharmacokinetics  
 
More information is available in the Investigator’s Brochure  and in Appendix I.  
 
3.4 Study Rationale  
This clinical study  will evaluate the use of MB-102 and the MediBeacon® Transdermal GFR 
Measurement System  for the purpose of marketing application with the final device design.   
 
4 Study Objectives  
The objectives of this pi[INVESTIGATOR_512487]:  
• To establish  that the MB -102 transdermal fluorescence measured GFR using the 
MediBeacon® Transdermal GFR Measurement System is comparable  to the measured MB -
102 plasma GFR   
• To evaluate the safety and tolerability of a single dose of MB-102 in subjects   
• To evaluate the safety and effectiveness of the MediBeacon® Transdermal GFR 
Measurement System for the non -invasive transdermal fluorescence detection of MB-102 
in subjects  
 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 14 of 57 
 5 Investigational Plan  
5.1 Overall Study Design and Plan  
Protocol 100-003 is a multi -center, open -label , pi[INVESTIGATOR_512488]-102 and the use of the MediBeacon® Transdermal GFR Measurement 
System  in normal and compromised renal function subjects with different skin color types  
comparing tGFR to plasma derived indexed GFR (nGFR) .  
 
Approximately 250 subjects are planned for enrollment. The US sites will plan to enroll 140 
evaluable  subjects; China sites  will enroll [ADDRESS_663204], and the MediBeacon® Transdermal GFR 
Measurement System  will be initiated to collect background fluorescence. When this is 
completed, subjects will the n receive a single dose of MB-102. Serial PK draws will be collected 
over a [ADDRESS_663205] enrolled the targeted number of evaluable subjects , the US 
clinical sites will be closed . The US data  alone  may be used to support the market authorization 
and approval in the US.  The completed OUS dataset, if available will be included in the US 
application.  
 
 
5.2 Overview of Study Procedures  
Potential subjects will be screened for eligibility within 21 days prior to planned dosing . Based 
on their screening eGFR (measured using the CKD -EPI [INVESTIGATOR_10908]), they will be assigned to 
Stratum 1 or Stratum 2:  
• Stratum 1: eGFR  ≥ 70 mL/min/1.73 m2 (50% of subjects)  
• Stratum 2:  eGFR < 70 mL/min/1.73 m2 (50% of subjects)  
 
Following pre -dose procedures to ensure eligibility, one sensor  will be affixed to the subject  on 
the upper chest in the area between the shoulders  (including the pectoralis and sternum area) .  
The subject  will then receive the MB-102 injection .  MB-102 will be administered by [CONTACT_512513] 30 – 60 seconds , followed by a salin e flush IV over 30 - 60 seconds . 
 
Stratum  1:  PK sampling will be collected pre -dose and at 5, 15, 30, 60, 90, 120, 180, 240, 300, 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663206] -dose (12 hour collection period) .  
 
Stratum 2:  PK sampling will be collected pre -dose and at 5, 15, 30, 60, 90, 120, 180, 240, 300, 
360, 480, [ADDRESS_663207]-dose (24 hour collection period).  
 
Safety assessments in the form of  vital sign s, safety labs, ECGs,  and adverse event collection  
will occur during the dosing day.  
 
Within 7 +/- 3 days of dosing, subjects will return to the study center for additional safety 
follow -up assessments.  
 
5.3 Discussion of Study Design  
The study is designed to validate the perform ance of the TGFR Measurement System.  
5.4 Selection of Study Population  
5.4.1 Number of Planned Evaluable Subjects  
A total of  188 evaluable  subjects are planned for enrollment . The population will be split into 
stratums  accordance with eGFR by [CONTACT_91019] -EPI [INVESTIGATOR_512489] : 
• Stratum 1: 50% of  subjects with an eGFR  ≥ 70 mL/min/1.73 m2 
• Stratum 2: 50% of  subjects with an eGFR < 70 mL/min/1.73 m2 
 
Subjects will be targeted across the spectrum of eGFR from normal through Stage 4 CKD.  
Subjects with an eGFR greater than 120 mL/min/1.73 m2 or less than 15 mL/min/1.73 m2 will be 
excluded. Efforts will be made to balance enrollment across the following eGFR levels  such that 
each subcategory has minimum of  10 subjects :  
• > 90 mL/min/1.73 m2  
• 60 – 89 mL/min/1.73 m2  
• 45 – 59 mL/min/1.73 m2  
• 30 – 44 mL/min/1.73 m2  
• 15 – 29 mL/min/1.73 m2  
 
Of the  evaluable  subjects, 1 40 will plan to be enrolled in the [LOCATION_002] and 48 will plan to be 
enrolled at sites in China .  
 
Approximately 50% of subjects within each stratum enrolled in the US  will be Fitzpatrick skin 
scale  (FSS)  I-III and 50% of subjects will have FSS IV-VI. In the US, subjects will be targeted 
across the full spectrum of FSS (I – VI) such that FSS cohorts  I-II, III-IV and V -VI will each 
enroll no less than 20 subjects.   
 
The FSS will not apply to subjects enrolled in China  because the population demographic is 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663208] satisfy all of the following criteria:  
Main Criteria for Inclusion:  
1. Age > 18 years – male or female  
a. Eligible female non -pregnant subjects who are either not of child -bearing 
potential or willing to use adequate contraception during the trial  
b. Males must be willing to practice abstinence or utilize adequate contraception 
from dosing day to at least [ADDRESS_663209] at screening, and agrees to one of the following acceptable 
contraceptive methods used consistently and correctly i.e. abstinence, oral 
contraceptive either combi ned or progesterone alone; injectable progesterone, 
implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive 
patches, IUD device or system or male partner sterilization  
d. Men will not donate sperm during the study and for [ADDRESS_663210] not meet any of the criteria noted below:  
1. Subjects positive via PCR testing for COVID -19 
a. Note: Vaccinated subjects without symptoms of COVID -19 are not required to 
undergo PCR testing but may be tested at the discretion of the study site 
2. Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior to 
the initial dose of the study medication; or more than 499 mL within 56 days prior to the 
initial dose of study medication  
3. Non-steroidal anti -inflammatory (NSAID) use within [ADDRESS_663211] 
within the following time ranges: prior to the first dosing day in the current study :  either  
[ADDRESS_663212] (whichever duration is longer).  
5. History of skin sensitivity to adhesives (e.g. Band -Aids, surgical tape)  
6. History of severe allergic hypersensitivity reactions (unacceptable adverse events) or 
anaphylactoid reaction to any allergen including drugs, MB-102 or other related products 
(intolerance to a drug is not considered a drug allergy ). 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663213] a poor 
candidate for participation in the clinical trial  
8. Significant scaring, tattoos or alterations in pi[INVESTIGATOR_512490]  
9. Any serious or uncontrolled medical disorder, active infection, physical exam finding, 
laboratory finding, or psychiatric condition that in the opi[INVESTIGATOR_512491]’ ability to complete study requirements or may put the subj ect at 
increased risk or compromise the interpretability of study results.  
10. Currently receiving dialysis  
11. Currently anuric  
12. Positive serum pregnancy test  
13. Subjects with an eGFR > 120 mL/min/1.73m2 
 
5.4.[ADDRESS_663214]’s care is provided .   
Reasons for withdrawal from the study may include one or more of the following:  
• Withdrawal of consent   
• Administrative decision by [CONTACT_978] [INVESTIGATOR_512492]   
• Adverse event requiring removal from the study  
• Physician prescribes a treatment that would conflict with the subject’s conti nued 
participation in the study   
Subjects withdrawing from the study will be encouraged to complete the follow -up study visit  
including all safety evaluations .  The reason(s) fo r withdrawal will be documented . 
Reasonable efforts will be made to contact [CONTACT_63381] -up.  All attempts and 
contacts must be documented in the subject’s file .   
The sponsor has the right to terminate the study at any time due to a safety issue or if special 
circumstances arise making further treatment of subjects impossible .  In this event, the 
investigator(s) will be informed of the reason for study termination.   
5.4.[ADDRESS_663215] a tGFR measured by [CONTACT_512514]® TGFR Measurement System (due to premature sensor removal, for example) or a 
major protocol deviation (such as a dosing extravasation) may be replaced  to ensure the 
minimum evaluable sample size is enrolled .  All subjects with exposure to MB -102 will be 
included in the safety analysis.   
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 18 of 57 
 5.5 Investigational Device  
MediBeacon® Transdermal GFR Measurement System  (TGFR)  is an investigational device that 
is intended to measure the Glomerular Filtration Rate (GFR) in patients with normal or impaired 
renal function by [CONTACT_512515]  (MB-102) over time.  
 
Site staff will place and affix the sensor s for all enrolled subjects . One sensor will be attached via 
adhesive pad to the upper chest . An adhesive clip, surgical tape or other means may also be used 
to alleviate tension on the sensor cord. Additional instructions for sensor placement will be 
provided in the Study Procedure Manual.  
 
The only parts of the MediBeacon® TGFR  that come into contact [CONTACT_512516] -
use adhesive pad , and the optical window .  The optical window protrudes very slightly from the 
adhesive, ensuring consistent contact [CONTACT_1155]’s skin.  The sensors  remain in contact [CONTACT_512517] a self -adhesive pad, typi[INVESTIGATOR_512493].  The sensor  remain s affixed to the subject  for at least 12.[ADDRESS_663216]’s skin  during the measurement period 
and after injection with MB-102, it will not be replaced and the subject will be discontinued from 
the measurement period of the study (but will remain in the trial to be followed for safety).  End 
of treatment assessments should be collected ( safety labs , vitals, and ECG). If a sensor dislodges  
from the skin  during the baseline period (prior to MB-102 injection), a new sensor may be used 
and the study re -started.  
The TGFR is designed to require a clean baseline (pre -injection of MB-102) in order to 
accurately measure GFR. If MB-102 is in the body at the time a sensor is attached, it will not 
allow measurement.  
5.5.2 Sensor Detachment from the TGFR Monitor  
If a sensor becomes detached even temporarily from the TGFR monitor , the data will be 
compromised and may not be used in the final analysis. However, the sensor should be re -
plugged into the monitor and the prompts on the screen should be followed so that fluorescent 
measurements can continue. This occurrence should be rec orded as a major protocol deviation  if 
the tGFR is NOT reported, and a minor deviation if the monitor displays  the tGFR .  
5.5.3 Identity of Investigational Device  
The MediBeacon® Transdermal GFR Measurement System  is manufactured  by [CONTACT_512518]. 
(St. Louis , MO, [LOCATION_003] ).  All packaging and labeling operations will be performed according to 
current Good Manufacturing Practice (GMP) , ISO [ZIP_CODE] and the relevant regulatory 
requirements.  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 19 of 57 
 5.5.4 Labeling  
Each MediBeacon® Transdermal GFR Measurement System  monitor and each  sensor  will be 
clearly labelled with a Serial Number  and REF MDB (Rev) .  
Each device  will be labelled with the following information:   
CAUTION  
Investigational Device.  
Limited by [CONTACT_512519].  
 
Additional labels will include the following information:  
REF MDB ####### Rev 0#  
LOT MDBNNNNNN -## 
SN. ########  
Non Sterile  
 
 
5.5.5 Storage, Supply and Return /Destruction   
Multiple investigational devices  (monitors and sensors) will be provided to the clinical sites . 
Disposable  items (sensors and any adhesive material ) will be single -subject use only. Devices 
and disposable materials must be stored in a secure location and are only for use during the 
clinical trial. All devices  (including any unused  single use sensors)  will be returned to the 
Sponsor at the conclusion of the trial. Instructions for return will be included in the Study 
Procedure Manual.  
5.5.[ADDRESS_663217] will be kept current and will contain:  
• Subject ID (screening number ) 
• Device(s) monitor  serial number   
• Sensor serial number  
• Date of dosing  
• Any observations noted during th e use of the device  
 
5.6 Investigational Drug  
MB-102 ( relmapi[INVESTIGATOR_512481])  is a bis -serine aminopyrazine that will be used as an exogenous 
fluorescent Glomerular Filtration Rate (GFR) agent.  This agent is excited by [CONTACT_512520].     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 20 of 57 
 emits green light.   
 
MB-102 has the following characteristics:  
 
• Produces fluorescence in vivo when excited by [CONTACT_491895], which can be reliably detected 
by [CONTACT_512521]-102 is injected intravenously  
• Has elimination kinetics that allows determination of GFR from fluorescence 
measurement within a clinic ally useful timeframe  
• Is filtered by [CONTACT_10521]  
• Is not protein bound  
• Is not expected to undergo se cretion or tubular reabsorption   
• Is not expected to be metaboliz ed by [CONTACT_512522]  
• Is not exp ected to affect kidney function  
• Has been shown to be safe in animal mo dels, in therapeutic dose range  
• Is photostable in its administration form and duri ng sample handling and analysis  
• Has been shown to be a GFR tracer age nt in nonclinical animal models  and early clinical 
studies  
 
5.6.[ADDRESS_663218]  
[IP_ADDRESS]  Active Pharmaceutical Ingredient (API)  
A sixty (60) month stability -testing program conducted under Good Manufacturing Practices 
(GMP) for the Active Pharmaceutical Ingredient (API) Lot # 07 -130227 -02/02 -43-01 (140 grams 
manufactured April 2013  by [CONTACT_512523]., formerly PharmaCore ) used in the Pi[INVESTIGATOR_2268] 1 and 2 
studies was completed. Stability condition s was 25°C ± 2°C, 60% ± 5% R.H. Results at [ADDRESS_663219] to the zero time parame ters. 
 
A sixty (60) month stability -testing program conducted under GMP for a second API [INVESTIGATOR_2268] ( [ADDRESS_663220] 2017  by [CONTACT_512524] ), API [INVESTIGATOR_512494] # 2337 -1706 -[ZIP_CODE] is on -going . Stability 
condition s was 25°C ± 2°C, 60% ± 5% R.H. Results show negligible degradation in active 
ingredient purity and essentially no change in the total impurity amount with respect to the zero 
time parameters at the four year time point.  
 
A third GMP API [INVESTIGATOR_16282] 1 kg was manufactured in June 2020  by [CONTACT_512524], Lot # 2337 -2004 -
[ZIP_CODE].  A sixty (60) month stability -testing program has been  initiated  and is ongoing  at 
conditions of 25°C ± 2°C, 60% ± 5% R.H.  Results show negligible degradation in active 
ingredient purity and essentially no change in the total impurity amount with respect to the zero 
time parameters at the  one year time point.  
 
[IP_ADDRESS]  Formulated Product  
A [ADDRESS_663221] Batch P02213  (~1500 
mL), manufactured  in April 2013  by [CONTACT_512525] (formerly Aptuit) from API [INVESTIGATOR_512494] # 07 -130227 -02/02 -
43-01, which was used for the Pi[INVESTIGATOR_2268] 1 A and 1B  studies, has been completed. Results show 
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  [ADDRESS_663222] to the zero time parameters for the 2 - 8°C condition.  
 
A [ADDRESS_663223] Batch P03915  (~3200 
mL), manufactured in May 2015 by [CONTACT_512526] [INVESTIGATOR_512494] # 07 -130227 -02/02 -43-01, and which 
was used for Groups 1 and 2 in Protocol ORFM Pi[INVESTIGATOR_2268] 2 study, has been completed. Stability 
condition was 2 - 8°C. Results show negligible degradation in active ingredient purity and 
essentially no change in the total impurity amount  with respect to the zero time parameters.  
 
Formulated product with designation Batch P04517 (~9000 mL) was manufactured under GMP 
conditions by [CONTACT_512527] [INVESTIGATOR_512494] # 2337 -1706 -[ZIP_CODE]. This batch was placed on stability at 2 - 
8°C for a three year period. At the [ADDRESS_663224] for use in Protocol 100 -003 are in the process of being 
manufactured.  Stability studies will be conducted on these lots .  
 
5.6.2 Identity of Investigational Drug  
MB-102 is packaged in amber vials at a concentration of 18.6 mg/mL in a 7.4 mL volume.   MB-
102 in formulation includes the following: sodium dihydrogen phosphate monohydrate, sodium 
hydroxide, sodium chloride, water for injection. Instructions for preparation of MB -102 will be 
included in the Study Procedure Manual.   
 
5.6.3 Investigational Drug Labeling  
MB-102 drug labels  for US distribution  include the following information:  
Relmapi[INVESTIGATOR_512481]  
7 mL of MB -102 Solution for injection only   18.6 mg/mL  
BMR No: MDBP0 5  Lot No: P03322/1  
Mfg. Date: 03/10/2022  Store at 2 °C - 8°C 
Caution: New Drug – Limited by [CONTACT_4496] ([LOCATION_002]) law to Investigational use.  
Manufactured for MediBeacon  
 
 
  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 22 of 57 
 MB-102 drug labels for China  distribution include s the following information:  
English  China  Distribution  
Protocol Number: 100 -003 
 
MB-102 (Relmapi[INVESTIGATOR_512481])  
18.6 mg/mL solution for injection  
Each single use  vial contains  7.[ADDRESS_663225] for IV use only . Please refer to the 
protocol.  
Store at 2°C - 8°C  
Lot No: xxxxx  
Expi[INVESTIGATOR_320]: TBD  
 
For clinical trial use only  
 
Sponsor: MediBeacon Inc.  
Manufacturer: Curia  (Scotland ) Ltd. 研究方案号 : 100 -003 
  
MB-102 ( Relmapi[INVESTIGATOR_512481])  注射液  
18.6 mg/mL  溶液  
每瓶含 7.4 mL MB -102 ( Relmapi[INVESTIGATOR_512481]) 注射液  
本品仅供静脉注射使用，按照研究方案使用  
2 - 8°C储存 
批号 : XXXXX  
使用期限： TBD  
  
仅用于临床试验  
  
申请人： MediBeacon Inc.  
生产商： Curia  (Scotland ) Ltd. 
 
 
5.6.4 Investigational Drug Storage, Supply, Return/Destruction  
Relmapi[INVESTIGATOR_512495] 2°C – 8°C in a secure location . Temperature records will 
be maintained by [CONTACT_977].  
 
All study medications will be stored, reconciled and either returned to the sponsor or destroyed 
according to applicable regulations following authorization by [CONTACT_512528].  
 
5.6.5 Investigational Drug Accountability  
Drug accountability will be maintained by [CONTACT_512529] 100% reconciled at the conclusion of the trial.  
Drug accountability documentation  may include, but may not be limited to, the following 
information:  
• Receipt date  
• Lot 
• Expi[INVESTIGATOR_4061] a nd/or manufacture date  
• Dispensing information  
 
5.[ADDRESS_663226] information  listed below:  
Joseph Pi[INVESTIGATOR_360101] , MD  ([LOCATION_002])  
Cell: +[PHONE_10645]    
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 23 of 57 
 Email : [EMAIL_9738]  
 
For China, the following individual should be contact[INVESTIGATOR_530]:  
 
[CONTACT_512550]  (Beijing, China)  
Phone: [PHONE_10646]  
Email:  [EMAIL_9739]  
 
For submission of Serious Adverse Event information or Unanticipated Adverse Device Effects, 
the following email maybe used:  
• Email : [EMAIL_9740]  
 
5.[ADDRESS_663227] including the nature of the therapy, the date/time of the procedure , and 
the reason for the therapy .  Concomitant medication information  taken at the time of a n SAE  will 
also be collected during the safety data follow -up.  
5.8.1 Prohibited Concomitant Medications  
The use  of NSAIDs  are prohibited 3 days prior to dosing for all subjects.  
5.8.2 Stable Use of Immunosuppressive Medications  
The protocol currently allows for subjects on immunosuppressant medications .  Those 
medications that fall into this category  are found in Table  1. This table also  outlines timelines 
around stability of those medications required at the time of enrolment.  
 
Table 1 Dose Stability Timelines for Subjects on Immunosuppressive Agents  
Immunosuppres sive Agent  Dose Stability Timeframe  
Antithymocyte Globulin (rabbit)  No changes within 90 days  
Basiliximab  No changes within 90 days  
Infliximab  No changes within 90 days  
Antithymocyte Globulin (equine)  No changes within 90 days  
Rituximab  No changes within 90 days  
Cyclosporine  No changes within 30 days  
Tacrolimus  No changes within 30 days  
 
 
6 Study Procedures  
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100 -003           V 4.0 
 
20 Sep  2022                                            CONFIDENTIAL   Page 24 of 57 
 6.1 Schedule of Assessments and Procedures  
The schedule of planned study assessments is shown in Table 2.
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003               V. 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 25 of 57 Table 2 Study Schedule of Events  
Period  Pre-Screen  
(optional)  Screen ing Dosing Day  Dosing Day  Dosing Day  Dosing Day  Follow -up Visit  
  21 days to day -2 
prior to Dosing  Pre-dose Dosing   
(time 0)  
 During 12 – [ADDRESS_663228] 
IP injection  7 days +/ - 3 days 
Informed Consenta X X      
Inclusion  / Exclusion  X X     
Demographics  X      
Medical History   X X     
Pregnancy Test for WOCBPb  X X     
PE or Limited PAc  X X    X 
Vital Signsd   X X  X X X 
Height and Weighte  X X     
Clinical Labsf    X X   X X 
Mexameter measurements    X     
Transdermal Data Collectiong   X X X X  
Drink water h   X X    
Administration of MB -102i    X    
PK blood collectionj   X  X X  
ECGk  X X   X  
Concomitant Therapi[INVESTIGATOR_512496]  X X  X X X 
Adverse Eventsm   X X X X X 
Document Fitzpatrick Skin 
Color Typ en X X      
MediBeacon Inc.     MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003               V 4.0 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 26 of 57 Table  2 Legend  
 
a. Pre-screen ing consent  may be used  to evaluate skin color only.  Full informed c onsent is required prior to any study related procedures being 
conducted.  
b. Negative pregnancy serum human chorionic gonadotropin (hCG) test at screening for women of childbearing potential ( WOCBP ) is required 
for eligibility. On dosing day, a urine pregnancy test will be conducted for WOCBP who agree to use a n acceptable  method of birth control  
c. A full physical examination (PE) is required at the screening visit.  A full PE or limited physical assessment (PA) m ay be conducted prior to 
dosing. (Limited PA includes assessments of HEENT, respi[INVESTIGATOR_696],  cardiovascular, abdominal systems). A full or limited exam may be 
conducted at the follow -up visit.  
d. Vital signs include blood pressure, respi[INVESTIGATOR_1487], heart rate and temperature.   Note: temperature is collected at screening, pre -dose, at 
approximately [ADDRESS_663229] -dose and at the follow -up visit  (and not during multiple timepoints  on dosing day ). Whenever possible, the 
subject should be resting for approximately [ADDRESS_663230] -dose timepoints: 90, 250 and 500 , 710 minutes  (±5 min).  For subjects followed for 24 hours, an additional measurement will be 
taken at 1450 minutes.  
e. Height and Weight should be measured at screening ; weight will also be measured on the day of dosing.  
f. Clinical laboratory assessments will be anal yzed by a central  laboratory  and consist of standard chemistry, hematology and urinalysis 
parameters  per Table 3. Coagulation  panel will be conducted at Screening only.   
g. MediBeacon® Transdermal GFR Measurement System  data collection will commence prior to dose administration. At least [ADDRESS_663231] and the MediBeacon® Transdermal GFR Measurement System started. Data collection will 
continue through [ADDRESS_663232] should be given 240 mL of ambient water to drink the night prior (if brought in the night before dosing), the morning of dosing , 
and just prior to MB -102 dose administration  
i. MB-102 will be administered as a dose of 130 mg (7 mL)  via IV injection over a 30 - 60 second injection period. This will be followed by a 
saline flush over 30 - 60 seconds. Time of administration will be recorded.  
j. Stratum 1:  PK sampling will be collected pre-dose and at 5, 15, 30, 60 , 90 (±2 min ), 120, 180, 240, 300, 360, 480, 600  (±5 min)  and [ADDRESS_663233] -dose (12 hour collection period). Stratum 2:  PK sampling will be collected pre -dose and at  5, 15, 30, 60, 90 (±2 min ), 120, 180, 
240, 300, 360, 480, 600 , 720, 960, 1200, and 1440 (±5 min)  minutes post-dose ( 24 hour collection period). Blood draws should be via a 
venous catheter and will be processed in accordance with instructions available in the Study Procedure Manual.  
k. A [ADDRESS_663234] dosing (±5 min ). Subjects should be resting quietly 
for 10 -15 minutes prior to the ECG collection.  
l. Concomitant medications administered within 3 days prior to baseline through the final follow -up visit will be recorded.   
m. Adverse events are collected from the time of sensor placement  (for baseline measurement)  through the follow -up visit . 
n. Fitzpatrick Skin Scale will be assessed by [CONTACT_512530] (where sensors will be placed). 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663235] the option to pre -screen study subjects to evaluate them directly for skin color 
in order to meet Fitzpatrick Skin Scale stratification recruitment requirements.   
6.3 Screening  
Screening will occur within 21 days (but at least 2 days prior to) the baseline / dosing day  and 
will comprise of the following:  
• Obtain written informed consent before any study -specific assessments are performed  
• Assess eligibility against the inclusion and exclusion criteria  
• Collect demographic data  and medical history ; review concomitant medications  
• Obtain  screening  non-fasting laboratory tests including chemistry, hematology,  and 
coagulation profile (See Section  [IP_ADDRESS]  and Table 3). Perform serum pregnancy test in 
women of child -bearing potential  and collect a urine sample for urinalysis . 
• Perform COVID -[ADDRESS_663236] performed  
• Collect height and weight measurements   
• Perform a full physical exam and collect vital signs  including temperature  (Section s 
[IP_ADDRESS]  and [IP_ADDRESS] ) 
• Perform a 12 lead ECG ( Section  [IP_ADDRESS] ) 
• Document Fitzpatrick Skin  Scale  Color Type  by [CONTACT_512531] (locations for 
possible sensor placement)  (see Appendix A ) 
6.4 Night before Dosing Day  
For institutions that prefer to bring study subjects to the institution the night before dosing day, 
the following procedures may be performed:  
• Review subject eligibility  
• Update medical history with any new information or issues since screening  
• Perform a limited physical assessment  
• Record concomitant medications taken within 3 days prior to dosing day  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 28 of 57 
 • Perform a urine pregnancy test for WOCBP  
• Have the subject consume 240 mL of ambient water  
6.5 Dosing Day: Baseline  Assessments  
Baseline assessments will be performed pr ior to dosing  (with the exception of those procedures 
noted in Section 6.3 that were performed the night before for those sites that bring subjects in the 
night prior to dosing) .  
• Update medical history with any new information or issues occurring since the initial 
screening visit  (if not performed the night before) .  
• Collect the subject weight  (BSA and BMI will be calculated based on screening height 
and baseline weight measurements)  
• Review subject eligibility  
• Confirm that the subject has consumed [ADDRESS_663237] 1 
hour prior to dosing time.  
• Perform a limited physical assessment and collect vital signs (including temperature) 
(Sections  [IP_ADDRESS]  and [IP_ADDRESS] ).  
• Perform a baseline ECG (Section [IP_ADDRESS] ). 
• Record c oncomitant medications  taken within 3 days of the dosing visit  
• For WOCBP, a urine pregnancy test will be performed  
• Clean and prepare the body areas for sensor attachment using an alcohol pad. Excess hair 
should be clipped  (not shaved)  from the area for sensor.  
• Obtain melanin (only) measurements with the Mexameter ( Section [IP_ADDRESS] ) 
• A venous catheter should be placed  in one arm  for PK blood draws.  A pre -dose baseline 
draw should be collected.  
• Obtain  baseline  laboratory tests i ncluding chemistry, hematology , and urinalysis  (See 
Section [IP_ADDRESS]  and Table 3).  
• Prior to  dosing, the device sensor should be attached to the subject  and the MediBeacon® 
Transdermal GFR Measurement System  data acquisition initiated . During this data 
acquisition period, no other study procedures should be performed.  
• Adverse event collection begins  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 29 of 57 
 • Prior to dosing, have the subject consume an additional 240 mL of ambient water  
• Place a venous catheter for the purpose of MB -[ADDRESS_663238] (22 – 24 
gauge).  
6.6 MB-102 Dosing  
The dose of 130 mg MB-102 (7.0 mL injection)  should be prepared based on instructions 
provided in the Study Procedure Manual . Final d ose calculation should be based on weight and 
not volume , therefore dosing syringes will be weighed prior to administration.   The prepared 
syringe should be maintained at ambient temperature . MB-[ADDRESS_663239] intravenous  (IV) injection following angio -catheter 
placement . Care should be taken to prevent extravasations during dosing.   Ideally, a 22 – 24 
gauge angio -catheter and 10 mL syringe should be used for administration. Catheter size will be 
collected.  
• Ensure Universal Standard precautions are taken with handwashing and gloving 
procedures; maintain aseptic technique when handling the prepared syringe  
• Check the patency of the placed catheter by [CONTACT_44579] a small volume  of saline  prior to 
MB-102 dosing  
• Administration of MB -102 should be via a steady IV injection (without hard pressure) 
over 30  - 60 seconds  (smaller bore catheters [24 gauge] may require a slower injection)  
• Following MB -102, a 10 mL saline flush should be administered over 30  - 60 seconds  
• The injection site should be observed for swelling or induration  or yellow discoloration 
indicative of a  drug infiltration . Drug infiltration may also cause discomfort or pain to the 
study subject.  
• The dosing catheter will be removed after the saline flush is completed.  
 
To avoid extravasation/infiltration:  
• Ensure no dislodgement of the needle cannula during venepuncture  
• Ensure the back vein wall is not punctured during placement  
• Avoid strong pressure on the syringe plunger during saline or MB -102 administration  
• Perform a slow injection over the full [ADDRESS_663240] it as both an adverse event and a protocol deviation.  Subjects 
with evidence of MB -102 or saline extravasations will be discontinued from PK collection and 
fluorescent measurements but followed for safety . Subjects may be replaced at the discretion of 
the Sponsor.  
 
The time noted at the completion of MB -102 injection  (but prior to the saline flush)  is the start -
time for the timing of the PK draws.  
Following dosing, the syringe will be weighed in order to calculate an accurate dose of MB-102.  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663241]-dose Study Procedures  
6.7.1 Stratum 1 (12 hour follow -up) 
During the course of the study day, it is particularly important for site teams to check the patency 
of PK catheters. If a catheter is determined to be compromised in anyway, another catheter may 
be placed in the same arm as the original catheter  utilizing a different vein .  
PK draws will be drawn via the venous  catheter at the following timepoints : 
• PK draw in K 2 EDTA tube at 5 minutes ( ±2 minute)  
• PK draw in K 2 EDTA tube at 15 minutes ( ±2 minute)  
• PK draw in K 2 EDTA tube at 30 minutes ( ±2 minutes)  
• PK draw in K 2 EDTA tub e at 60 minutes ( ±2 minutes)  
• PK draw in K 2 EDTA tube at 90 minutes ( ±2 minute)  
• Vital sign collection at 90 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 120 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 180 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 240 minutes ( ±5 minutes)  
• Vital sign collection at 250 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 300 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 360 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 480 minutes ( ±5 minutes)  
• Vital sign collection at 500 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 600 minutes ( ±5 minutes)  
• Perform a 12 lead ECG at 700 minutes ( ±5 minutes)  
• Vital sign collection (includes temperature) at 710 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 720 minutes ( ±5 minutes)  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 31 of 57 
 • Obtain  laboratory tests including chemistry, hematology, and urinalysis ( See Section 
[IP_ADDRESS]  and Table 3) at 725 minutes (±5 minutes)  
• At the conclusion of TGFR measurements  (when tGFR is reported on the monitor) , the 
sensor may be removed  
• Adverse events will be collected based on subject  reports  and medical team observations  
6.8 Stratum 2 ( 24 hour follow -up) 
PK draws will be drawn via the venous  catheter at the following timepoints:  
• PK draw in K 2 EDTA tube at 5 minutes ( ±2 minute)  
• PK draw in K 2 EDTA tube at 15 minutes ( ±2 minute s) 
• PK draw in K 2 EDTA tube at 30 minutes ( ±2 minutes)  
• PK draw in K 2 EDTA tube at 60 minutes ( ±2 minutes)  
• PK draw in K 2 EDTA tube at 90 minutes ( ±2 minute)  
• Vital sign collection at 90 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 120 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 180 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 240 minutes ( ±5 minutes)  
• Vital sign collection at 250 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 300 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 360 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 480 minutes ( ±5 minutes)  
• Vital sign collection at 500 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 600 minutes ( ±5 minutes)  
• Perform a 12 lead ECG at 700 minutes ( ±5 minutes)  
• Vital sign collection (includes temperature) at 710 minutes ( ±5 minutes)  
• PK draw in K 2 EDTA tube at 720 minutes ( ±5 minutes)  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 32 of 57 
 • Obtain  laboratory tests including chemistry, hematology, and urinalysis ( See Section 
[IP_ADDRESS]  and Table 3) at 725 minutes (±5 minutes)  
• PK draw in K 2 EDTA tube at 960 minutes (±5 minutes)  
• PK draw in K 2 EDTA tube at 1 200 minutes ( ±5 minute)  
• PK draw in K 2 EDTA tube at 1440 minutes (±5 minutes)  
• Vital sign collection at 1450 minutes (±5 minutes)  
• At the conclusion of TGFR measurements  (when an tGFR is reported on the monitor) , 
the sensor may be removed .  
• Adverse events will be collected based on subject  reports  and medical team observations  
• Subjects may be discharged from the study center  
6.9 Follow -up Visit  
Subjects will return for a safety follow -up visit approximately 7 +/-3 days after the dosing  visit. 
The following assessments will be performed  
• Perform a full or limited physical exam and collect vital signs  including temperature  
(Sections  [IP_ADDRESS]  and [IP_ADDRESS] ) 
• Obtain  laboratory tests including chemistry, hematology, and urinalysis (Section [IP_ADDRESS]  
and Table 3).   
• Record c oncomitant medications   
• Collect adverse events ; review ongoing AEs and document resolution (when applicable)   
6.10 Early Withdrawal / Unscheduled Visits  
Any subject that withdraws from the study early for any reason, or who needs to have an 
unscheduled visit performed to assess a safety issue, will have the following assessments 
performed:  
• Obtain laboratory tests including chemistry, hematology, and urinalysis profile ( Section 
[IP_ADDRESS]  and Table 3). 
•  Perform a full or limited physical exam and collect vital signs  (Sections  [IP_ADDRESS]  and 
[IP_ADDRESS] ) 
• Record concomitant medications  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 33 of 57 
 • Collect adverse events ; review ongoing AEs and document resolution (when applicable)  
• Record withdrawal date and reason for withdrawal, if appropriate  
6.11 Repeat Subjects  
Subjects may be re -enrolled in the protocol in the following situations  (and if no documented 
safety concerns regarding exposure to the investigational device or drug) :  
• When a dose extravasation has occurred  
• When there is a device malfunction (sensor falling off during the monitoring period and 
before a tGFR  has been reported ) 
• Back -up subjects who were not dosed  
Stratum [ADDRESS_663242] a minimum of a 7 -day wash -out 
from prior exposure of MB -102 before receiving another dose   
In some cases, the screening visit (if outside the 21 -day window) may need to be repeated.  
Repeat subjects will maintain the same subject ID .  
Subjects can be in the study a maximum of two times and only when the above situations have 
occurred.  
7 Efficacy and Safety Variables  
7.1 Efficacy and Safety Measurements Assessed and Flow Chart  
Table 2 shows the planned study assessments .   
7.1.1 Efficacy Assessments  
This pi[INVESTIGATOR_512497]-102 and the MediBeacon® Transdermal GFR Measurement System  to provide a point of 
care (POC) means to collect GFR data. The specific endpoints related to calculation of GFR are 
discussed in Section 9. 
7.1.2 Safety Assessments  
Safety will be monitored by [CONTACT_512532] . Planned safety assessments are detailed in the MediBeacon® 
Transdermal GFR Measurement System  Study Schedule  (Table 2). The i nvestigators or site staff 
will be responsible for monitoring the safety of subjects who have entered this study and will be 
responsible for detecting, documenting and reporting events that meet the definition of an  
adverse event  (AE) or serious adverse event ( SAE ).  Significant findings that were noted to be  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663243] be recorded on the AE page of 
the eCRF. Subjects should be followed until the event is resolved or stabilized . AEs are collected 
from the time of initial sensor placement  until the co mpletion of the follow -up visit .   
[IP_ADDRESS]  Adverse Events  
Adverse Event Definition  
An a dverse event is defined as any untoward medical occurrence, unintended disease or injury, 
or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally 
associated with the use of a medicinal product, whether or not related to the investigational 
medical device  or drug . 
An unanticipated adverse device effect (UADE) is any serious adverse effect on health or safety, 
any life -threatening problem or death caused by, or associated with a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 
application;  or any other unanticipated serious problem associated with a device that relates to 
the rights, safety, or welfare of subjects . For the purposes of this trial, the device is the 
MediBeacon® Transdermal GFR Mea surement System  and the sensor system including the 
adhesive pads for the attachment of the optical sensors to the body.  
Documentation and Reporting of Adverse Events  
AEs should be reported and documented in accordance with the procedures outlined below . The 
following data should be documented for each AE:  
• Description /term  of the symptom event  (underlying diagnosis)  
• Date of first occurrence and dat e of resolution (if applicable)  
• Classification of “serious ” or “not serious ” (Section  [IP_ADDRESS] ) 
• Severity  
• Causal relationship   
• Action taken  
• Outcome of event  
For abnormal clinically significant laboratory findings, the clinical manifestation (diagnosis) 
should be noted as an adverse event  (e.g. anemia instead of low hemoglobin) . Should a clinically 
significant lab abnormality occu r that is not part of a diagnosi s, the abnormality itself may be 
reported as an AE. Laboratory abnormalities that meet the criteria for an AE should be followed 
until they have returned to normal or an adequate explanation of the abnormality is determined. 
When an abnormal laboratory result corresponds to a sign/symptom of an already repo rted AE it 
is not necessary to separately record the lab result a s an additional AE.   
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 35 of 57 
 Assessment of Severity  
Each AE will be assigned a category by [CONTACT_3470]:  
• Mild:  results in minimal transient impairment of a body function or damage to a body 
structure and/or does not require any intervention other than monitoring or OTC 
medication.  
 
• Moderate:  Results in moderate transient impairment of a body function or transient 
damage to a body structure and/or requires intervention, such as administration of 
medication or transfusion or laparoscopic or endoscopic procedure to prevent permanent 
impairment o f a body function or damage to a body structure.  
 
Severe:  An event which is life threatening, results in permanent impairment of a body 
function or permanent damage to a body structure or necessitates significant intervention, 
such as major surgery, to prevent permanent impairment of a body function or permanent  
damage to a body structure. The term severe is often used to describe the intensity 
(severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the 
event itself, however, may be of relatively minor medical significance (such as  severe 
headache). This is not the same as serious, which is based on patient/event outcome or 
action criteria usually associated with events that pose a threat to a patient‘s life or 
functioning. Seriousness (not severity) serves as a guide for defining r egulatory reporting 
obligations.  An event that changes in severity (gets worse or gets better) should be noted 
as its worst severity.  
 
Assessment of Causality  
Every effort will be made by [CONTACT_63398], if any, to the 
study device  (and components), investigational  drug.  Causality should be assessed using the 
categories presented below : 
Unrelated  Clinical event with an incompatible time relationship to study device  or 
study drug , and that could be explained by [CONTACT_512533] . 
Unlikely  Clinical event whose time relationship to study device  investigational 
drug makes a causal connection improbable, but that could plausibly be 
explained by [CONTACT_512534].  
Possible  Clinical event with a reasonable time relationship to study device or 
investigational drug , but that could also be explained by [CONTACT_322260].  
Probable  Clinical event with a reasonable time relationship to study device or 
investigational drug and is unlikely to be attributed to concurrent disease 
or other drugs.  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 36 of 57 
 Very Likely/Certain  Clinical event with plausible time relationship to study device or 
investigational drug , and that cannot be explained by [CONTACT_512535].  
AEs that are deemed related should be further assessed to determine if a relationship to the 
investigational drug, or device can be elucidated .  
Action Taken  
The investigator will describe the action taken in the appropriate section of the eCRF , as follows:  
• None  
• Concomitant interventional treatment(s) administered  (includes medications or 
procedures)  
• Other, specify  
Outcome of the Event  
The investigator will describe the outcome of the event in the appropriate section of the eCRF, as 
follows:  
• Unknown  
• Resolved  
• Ongoing  
• Resolved  with sequelae  
• Death (with date and cause reported)  
 
Follow -up of Adverse Events  
Subjects with AEs should be followed until the event is resolved or until, in the opi[INVESTIGATOR_512498] , the event is stabilized or determined to be chronic . 
[IP_ADDRESS]  Serious Adverse Events  
Serious Adverse Event Definition  
An SAE is any AE from this study that results in one of the following outcomes : 
 
An adverse event that:  
a) led to death;  
b) led to serious deterioration in the health or the subject, that either resulted in:    
1) a life threatening illness or injury or  
2) a permanent impairment of a body structure or a body function, or  
3) in-patient or prolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function;  
 c) led to fetal distress, fetal death or a congenital abnormality or birth defect  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 37 of 57 
  
Reporting requirements for all SAEs is detailed in Section [IP_ADDRESS] .  
Note: Planned hospi[INVESTIGATOR_272] a pre -existing condition,  or a procedure required by [CONTACT_13746], is not considered a serious adverse event.  
 
[IP_ADDRESS]  Reporting of Serious Adverse Events  
Any SAE must be reported by [CONTACT_512536]® Transdermal GFR Measurement 
System , or the  investigational drug .  All serious adverse events must be reported by [CONTACT_3786] (or designee) by [CONTACT_512537]  (via the 
electronic data capture (EDC) system) or via email  to MediBeacon  within [ADDRESS_663244] (UADE)  or as an expedited 
serious adverse event .  
Note: It is also the responsibility of the Investigator to inform their Independent Ethics 
Committee ( IEC) of other serious adverse events (i.e. non -UADEs) as required by [CONTACT_512538] . 
 
SAE s must be  reported within 24 hours of knowledge .  
For submission of Serious Adverse Event information or Unanticipated Adverse Device Effects, 
the following email maybe used:  
Email : [EMAIL_9740]  
 
The investigator should not wait to receive additional information to document fully the event 
before notification  to the Sponsor  of an SAE, though additional information may be requested .  
Where applicable, information from relevant laboratory results, hospi[INVESTIGATOR_63337] , and 
autopsy reports should be obtained.  
Instances of death, congenital abnormality , or an event that is of such clinical concern as to 
influence the overall assessment of safety, if brought to the attention of the investigator at any 
time and linked by [CONTACT_63402], should be reported to MediBeacon .   
The sponsor or designee will promptly notify all relevant investigators and the regulatory 
authorities of findings that could adversely affect the safety of subjects, impact on the conduct of 
the study or alter the IEC approval/favorable opi[INVESTIGATOR_23748] .  In addition, the sponsor, will 
expedite the reporting to all concerned investigators, to the IECs, and to the regulatory 
authorities of all adverse device reactions that are both serious and unanticipated .   
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 38 of 57 
 [IP_ADDRESS]  Pregnancies  
Testing  for pregnancy for a female study subject with childbearing  potential must be conducted 
at screening  (or within 7 days of dosing) .  In addition, a urine pregnancy test will be performed 
prior to dosing on treatment day. Subjects who are pregnant or intend to become pregnant during 
the study will be excluded. Should a pregnancy occur with a study subject, the  pregnancy  should 
be reported to MediBeacon  within 24 hours of the site’s knowledge . All pregnancies will be 
followed to term , delivery or premat ure termination .  
[IP_ADDRESS]  Devic e Observations / Malfunctions  
All device observations, malfunctions or failures of the MediBeacon® Transdermal GFR 
Measurement System  will be documented in the eCRF. In addition, failures of the sensor 
adhesive will be specifically documented.  
 
[IP_ADDRESS].1  Sensor Displacement  
Prior dosing with  MB-102: 
Should a sensor be accidently removed (or significantly bumped) prior to receipt of MB -102, it 
should be removed from the subject, a new sensor placed  on the subject,  and baseline 
measurements re -started.  
 
After dosing with  MB-102: 
If a sensor is accidently removed (or significantly bumped) following receipt of MB -[ADDRESS_663245] will remain in the study for safety follow -ups only  for 
the full duration required by [CONTACT_512539] (12 hours or 24 hours) . PK sample collection and 
fluorescent measurements  will be terminated, however safety assessments (vital signs, ECGs and 
clinical safety labs) will be performed.  
 
[IP_ADDRESS]  Clinical Laboratory Evaluation  
Clinical laboratory assessments  (Table 3) will be performed by a central lab  in the US . A central 
lab will be used in China, if available. If the central lab is unavailable due to COVID -19, Chinese 
sites may utilize their local hospi[INVESTIGATOR_512499].  Reference ranges will 
be used by [CONTACT_512540] .  Clinically significant changes in laboratory values will be 
documented as adverse events.  
  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 39 of 57 
  
Table 3 Clinical Laboratory Analytes  
Chemistry Panel                                    Hematology       Other required lab tests  
• Alkaline Phosphatase   
• Alanine Aminotransferase  (ALT)  
• Albumin  
• Aspartate Aminotransferase  (AST)  
• Bilirubin (total and direct)  
• Blood Urea Nitrogen  (BUN)  
• Calcium (Ca)  
• Carbon dioxide (CO2)  
• Chloride  (C) 
• Creatinine  (SCr)  
• Glucose  
• Phosphorus  
• Potas sium   
• Sodium  
• Total Protein  
• Uric acid  
• BUN/Creatinine ratio  
 
 
 
All lab tests are non -fasting  • Hematocrit  
• Hemoglobin  
• WBC  
• RBC  
• Platelets  
Differentials  
• Neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
 
 For WOCBP  
• Serum pregnancy test 
(screening and a urine 
dipstick on day of 
dosing  
• Urinalysis  
• Protein  
• Glucose  
• Ketones  
• Hemoglobin  
• Bilirubin  
• Urobilinogen  
• Acetone  
• Nitrite  
• Leucocytes  
• pH 
• Specific gravity  
• Color  
• Bacteria  
If abnormalities are seen, 
then microscopic 
examination will be 
performed  Coagulation 
Parameters  
Only performed 
at screening  
• PT 
• INR 
• aPTT  
 
COVID -[ADDRESS_663246]: nasopharyngeal swab (only performed at screening for unvaccinated 
subjects or per study center requirements)  
 
[IP_ADDRESS]  Vital Signs  
Vital signs (including blood pressure,  heart rate, respi[INVESTIGATOR_1516], and temperature)  will be measured 
at screening, at multiple timepoints on dosing day (s), and at the follow -up visit. Vital signs 
should be collected while the subject is in a seated position and after resting for approximately 5 
minutes for all measurements.  Temperature is only collected at screening, pre -dose, and the 
completion of the dosing day,  and at the follow -up visit .  
[IP_ADDRESS]  Physical Exam ination s or Limited Physical Assessments  
Physical exam ination s (when conducted by a physician , or other medically qualified 
investigator ) or limited physical assessments (when performed  by a nurse or other qualified 
individual ) should include at a minimum an assessment of the head, ears, eyes, nose, throat 
(HEENT), respi[INVESTIGATOR_696], cardiovascular, and gastrointestinal systems . It is preferred that the same 
medical professional perform the baseline and post dosing assessments. Significant findings that 
were present prior to dosing must be included in t he Medical History eCRF page. Significant 
new findings that begin or worsen after dosing must be recorded on the AE page of the eCRF. 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663247] for assessing the AE  
[IP_ADDRESS]  ECGs  
Standard 12 lead ECGs will be collected at  screening , prior to dosing and at 700 minutes (±5 
min) . The following parameters will be assessed: interpretation, ventricular rate, PR interval, 
QRS duration, QT, and QTcF.  
 
Subjects should be allowed to rest quietly approximately [ADDRESS_663248] 
with an abnormal not clinically significant ECG does not qualify for dosing without investigator 
comment on the ECG source document/eCRF.  
 
[IP_ADDRESS]  PK Sample Collection  
PK samples will be collected at the timepoints noted in  Table 2. Recommendations for venous 
access and  sample processing information are  available in the Study Procedure Manual. PK 
samples should be collected in a manner to prevent haemolysis  and placed on ice until processed 
and aliquoted into cryovials. PK samples must be stored frozen at   -70 to -80ºC until shipped for 
PK analysis.  
 
[IP_ADDRESS]  Mexameter® Measurements  
A commercially available Mexameter® device will be provided to the sites for the measurement 
of skin pi[INVESTIGATOR_2517] (melanin) and erythema.  The device should be used in accordance with the 
instructions provided in the Study Procedure Manual (including pre -use calibration). 
Measurements should be performed on subjects when they are not in close proximity to a 
window and  should be made on the  approximate location of sensor placement. It is advisable, 
when required, to clip excess hair as early in the dosing day as possible to allow transient redness 
due to the clippi[INVESTIGATOR_512500].  The site should note any skin irritation due to clippi[INVESTIGATOR_512501] . Mexameter® measurements of melanin will be collected prior to sensor 
placement.  
7.2 Safety Review Committee  
A Safety Review Committee (SRC) will be convened and will include the medical monitor, the 
safety manager (s), clinical monitor(s) and clinical manager.   The SRC will oversee safety data 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 41 of 57 
 (AEs, vitals, clinical labs, ECG data, etc.) generated by [CONTACT_512541]. In 
addition, they will review all SAEs and UADEs and clinically significant safety observations 
noted during the study. Oversight work  and study related decisions  will be performed in 
accordance with a written Safety Review Committee Plan.  
8 Information for the Investigator: Potential Risks of the Device  
Adverse events that may be anticipated in this clinical study are outlined for t he investigational 
drug and the MediBeacon® Transdermal GFR Measurement System . 
 
8.1 Investigational Drug  
Clinical d ata from the Pi[INVESTIGATOR_2268] 1 A and 1 B studies  (total n = 32 subjects) include d the following 
adverse events:  
• Pi[INVESTIGATOR_2268] 1 A (n = 16)  
o Vasovagal reaction  ([ADDRESS_663249])  
o Dizziness  ([ADDRESS_663250], 2 events)  
 
These events occurred in fasting subjects shortly after dosing and resolved on that day.  No other 
AEs, injection site reactions, clinically significant laboratory values or significant changes in 
vital signs were noted during this study.  
 
• Pi[INVESTIGATOR_2268] 1 B (n = 16)  
o Headaches  (56.3% of subjects)  
o Erythema  (at the site of the adhesive)  (100% of subjects)  
o Diarrhoea  ([ADDRESS_663251])  
o Dizziness (occurring in [ADDRESS_663252] following release from the study center ) 
 
Erythema was thought to be related to the adhesive used to adhere the sensor to the skin. 
Headaches were  deemed  related to the head strap required to hold the forehead sensor in place. 
Sensor placement on forehead was discontinued post Pi[INVESTIGATOR_2268] 1B.   
 
MB-102 is excreted in the urine. Therefore , urine discoloration  (chromaturia)  is expected but has 
not been considered an adverse event in prior studies.  
 
In the Pi[INVESTIGATOR_2268] [ADDRESS_663253] been 
exposed to MB -102. A total of 120 subjects received a dose of 4 µmol/kg followed by a 5 mL 
injection of iohexol. Seventy (70) subjects received a single dose only (no iohexol) of 4 µmol/kg 
of MB -102) and [ADDRESS_663254] received a fixed dose of 130 mg (7 mL). All reported AEs were mild or 
moderate in severity and resolved without sequalae.  Overall, MB -[ADDRESS_663255] population.  
 
A total of 40 adverse events were reported in 28 treated subjects in Groups 1, 2 and 3 for an AE 
rate of 12.0% in the treated population. A total of 31 events were considered mild and 9 
moderate events occurred in 5 subjects (2.5% of the population). There  were no severe events 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 42 of 57 
 reported. There were no Serious Adverse Events (SAEs) reported during the study. There were 
no Unanticipated Adverse Device Effects (UADEs) reported during the study.   
 
Four AEs, dyspepsia, chromaturia, hot flush and (facial) rash were considered related to 
investigational product (MB -102); all events resolved by [CONTACT_90142]. Dyspepsia and 
chromaturia were also considered to be related to iohexol. Of note, chromaturi a is an expected 
effect of MB -102 (noted in the Investigator’s Brochure) and expected in all subjects as the 
excretion of MB -[ADDRESS_663256] of iohexol (per the label).   
 
Seven (7) AEs occurring in 7 subjects were considered related to the device (sensor attachment); 
these included application site erythema, dermatitis, and pruritus and were considered related to 
the adhesive material used to hold the sensor in place. Two e vents of application site 
discoloration (melanin spot at the sensor location) were noted in 2 subjects in the SOG cohort 
which resolved within 24 hours of removal of the sensor.  Other reported AEs (conjunctivitis, 
nausea, vomiting, cardiac murmur, headach e, anxiety, micturition urgency, pollakiuria, urine 
odor abnormal, peripheral oedema, fatigue, and a pruritis event [not at the sensor location] were 
considered not related to MB -102, the sensor device or iohexol.  Injection site reactions 
(bruising, eryth ema, extravasation) were also not considered related to MB -102.   
 
There may also be other risks that are unforeseen at this time.  For additional information on the 
risk profile, please reference the current Investigator ’s Brochure .  
 
8.2 MediBeacon® Transdermal GFR Measurement System   
There are no direct risks associated with the MediBeacon® Transdermal GFR Measurement 
System  (monitor portion)  as it does not contact [CONTACT_1177] .  Adverse events observed from 
the sensors are with regard to the methods used to affix it to the study subject.   Risks may 
include a reaction to the sensor or adhesive material  or the adhesive used on the skin clip .  
8.2.1 Adhesive Clip  
As with the adhesive used on the sensors, there is the chance of reaction to the adhesive used to 
attach the clip to the skin.  Reactions could include redness, itchiness or other localized skin 
reactions.  Clips will be provided, however other means (surgical tape, tegaderm, etc.) to secure 
the sensor cord may be used.  
8.[ADDRESS_663257] of blood loss.  
Bruising and pain at the site of the venous catheter s may also be expected.  
 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663258] may report pain or burning during the injection. 
Subjects should be queried during the injection regarding any sensation. Subjects with MB -102 
or saline extravasations will be discontinued from PK collection a nd fluorescent measurements 
but continued in the study for safety. All extravasations will be collected as adverse events and 
protocol deviations.  
9 Statistical Methods  
9.1 Overview   
The transdermal -derived GFR data (tGFR) is obtained directly from the MediBeacon® 
Transdermal GFR Measurement System (TGFR) for each subject. This tGFR value is compared 
to the subject's nGFR BSA for the study endpoint determination.  
 
9.2 Analysis Populations  
The following analysis populations will be defined for the study:  
➢ Intent -to-Measure (ITM) Population  – The ITM population will consist of all subjects 
who are enrolled in the study in Stratum 1 & [ADDRESS_663259] not had any major protocol deviations.  
➢ Modified Intent -to-Measure (mITM) Population  – The mITM population will consist 
of all subjects in the ITM population with no outlier PK parameters.  
➢ Safety Population  – The safety population will consist of all subjects who are enrolled in 
the study and have been dosed with MB -102.   
➢ Pharmacokinetic (PK) Population  – The pharmacokinetic population will consist of all 
subjects who are enrolled in the study and have any PK data.  
The mITM population will be the primary analysis set for all effectiveness analyses.  The 
Safety Population will be used for the analysis of all safety variables and baseline 
characteristics. The PK Population will be used for the analyses of PK data.  
 
9.[ADDRESS_663260] completed the study if they complete the dosing da y.  
The number and percentage of subjects in each analysis population will be presented.  
Percentages will be based on the number of subjects enrolled.  
9.4 Plasma Pharmacokinetic A nalyses  
The pharmacokinetic objective is to characterize the single dose pharmacokinetics  of MB -102 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 44 of 57 
 following IV bolus dosing , specifically, to obtain the clearance and total volume of distribution 
of MB -102 using compartmental methods in  Phoenix WinNonlin (Certara, Version 8.1 or 
higher) . 
 
Based on prior data, it is expected that a two -compartment model will adequate ly describe the 
pharmacokinetic profiles of MB -102. T he following two-compartmental pharmacokinetic 
parameters will be determined : 
 
➢ Cmax: The maximum plasma concentration.  
➢ AUC: Area under the plasma concentration -time curve  
➢ t1/2α: Half-life associated with distribution phase  
➢ t1/2β: Half -life associated with elimination phase  
➢ t1/2: elimination half -life from central compartment .   
➢ V: Total volume of distribution  
➢ CL: Systemic clearance  
➢ V1: Volume of distribution for central compartment  
➢ V2: Volume of distribution for peripheral compartment  
 
The two key PK parameters from compartmental analysis are CL and V. The clearance (CL) 
derived from the two -compartment model is the plasma -derived GFR used to calculate the BSA 
indexed nGFR that is the comparison to the tGFR for the P30 calculations. V is  used in the 
calculation of GFR indexed to volume of distribution.  
 
All PK concentrations and parameters will be listed. As each subject will have a unique GFR 
measurement, summary statistics are not applicable in this analysis.  
Individual figures will be provided for plasma PK concentrations. All figures will be produced 
on both linear -linear and logarithmic - linear scales with data and the two -compartment fit.  
 
9.[ADDRESS_663261] to the plasma -derived indexed GFR, with a 95% confidence interval. The performance 
goal is 85%. Success for the study will be that the lower limit of the 95% CI  is greater than 85%.  
 
9.6 Safety Analyses  
Safety of MB-102 will be evaluated through treatment emergent adverse events (TEAEs), where 
treatment emergence is defined with respect to the first dose of MB-102. 
 
Safety of the MediBeacon® Transdermal GFR Measurement System  will be evaluated through 
TEAEs, where treatment emergence is defined with respect to the start time of Transdermal GFR 
Measurement System  use (placement of the sensor on the skin) . 
 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 45 of 57 
 Additional safety variables include physical examinations, clinical laboratory assessments, 
ECGs, and concomitant medication use.  
 
All s afety analyses will be done for subjects receiving a single dose of MB-102. 
 
9.6.1 Treatment -Emergent Adverse Events  
AEs will be coded using the Medical Dictionary for Regulatory Activities  (MedDRA). The 
system organ class and preferred term for each AE will be available, along with the verbatim 
reported term, event start and stop dates/times, seriousness, severity, relationship to 
treatment/device, action taken, and event outcome. SAEs will  also be documented in a case 
narrative format.  
The overall numbers and percentages of subjects who experienced any treatment -emergent AEs 
(TEAE s) will be presented.  TEAEs will also be summarized at the subject level  by [CONTACT_59134] , and at the event level by [CONTACT_9313]/preferred term and severity 
and by [CONTACT_9313]/ preferred term and relationship to treatment . 
9.6.2 Physical Examinations/Limited Physical Assessments  
The results of physical examinations will be collected as adverse events if clinically significant  
or as medical history (if observations are noted prior to TGFR start ).  Physical exam data will not 
be listed.  
9.6.3 Clinical Laboratory Assessments  
Clinical laboratory tests include clinical chemistry, hematology, urinalysis and coagulation 
parameters. Each parameter will be summarized using the descriptive statistics.  Details will be 
specified in the Statistical Analysis Plan (SAP).  Also, individua l subject results will be assessed 
against an appropriate reference range if available.  The manifestation of any clinically 
significant abnormality that develops during the study will be reported as an AE.  
9.6.4 ECGs  
ECG data will be listed. Clinically significant findings will be noted as adverse events.  
9.6.5 Prior and Concomitant Therapi[INVESTIGATOR_512502] 3 days prior to  MB-102 dose administration  and 
through the follow -up study visit  will be listed. Medications will be coded using the World 
Health Organization (WHO) drug dictionary. Data will be provided in one or more subject data 
listings. Concomitant non -drug therapi[INVESTIGATOR_275408].  
9.7 Determination of Sample Size  
For a P30 true value of 0.95, alpha of 0.025, performance goal of 85%, power of 90%, the one -
sided exact binomial test yields a sample size of 102.  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663262] sites with the operation of  the MediBeacon® Transdermal GFR Measurement System .  
 
10.[ADDRESS_663263] will be recorded in an electronic data capture (EDC) system.   Data 
collection must be completed for each subject enrolled in the study .   
In accordance with GCP and International Conference on Harmonization ( ICH) guidelines, the 
study monitor will conduct monitoring visits at regular intervals .  During the visits, the study 
monitor will perform the source document verification and verification that investigator’s 
obligations and all applicable regulatory requirements are being fulfilled .  The frequency of 
monitoring visits will be determined by [CONTACT_512542].   
The investigator must permit the monitor, the IEC, the sponsor’s internal auditors and 
representatives from regulatory authorities direct access to all study -related documents and 
pertinent hospi[INVESTIGATOR_884] , including direct access to electronic medical records for 
confirmation of data contained within the EDC system .  Subject confidentiality will be protected 
at all times.  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 47 of 57 
 10.4 Data Management and Coding  
MediBeacon or designee will be responsible for activities associated with the data management 
of this study .  This will include setting up a relevant database and data transfer mechanisms, 
along with appropriate validation of data and resolution of queries .  Data generated within this 
clinical study will be handled according to the relevant SOPs at MediBeacon or their designee . 
Study sites will enter data  into a 21 CFR Part 11 compliant electronic data capture (EDC) system 
via a secure internet connection .  Data entered into the EDC system  must be verifiable against 
source documents at the study site . Any changes to the data entered into EDC system will be 
recorded in the audit trai l. 
Missing or inconsistent data will be queried via the EDC system to the investigator for 
clarification .  Subsequent modifications to the database will be documented.  
Fluorescent data from the TGFR System will be downloaded to hard media then transferred 
electronically to the Data Management designee via a secure data transfer process  per the Study 
Procedure Manual.  
All medical terms (medical history, concomitant medications and adverse events) will be coded.  
10.[ADDRESS_663264]’s risk or affect the validity of the study.  In 
medical emergencies, prior written approval for protocol deviations will not  be required, but 
MediBeacon  or their designee must be notified via telephone within 24 hours of occurrence.  
Prospective approval of protocol devia tions to recruitment and enrolment  criteria (also known as 
protocol waivers or exemptions ) are not permitted.   
 
Major Protocol Deviation is a significant deviation from the protocol that may impact subject 
safety and/or affect the integrity of clinical trial data.  These may include, but are not limited to 
the following:  
 
• Improper or inadequ ate informed consent procedures  
• Subject did not meet eligibility criter ia 
• Subject received prohibited concomitant medication( s) at any time during the trial  with 
the exception of low dose aspi[INVESTIGATOR_248] (which would be considered a minor deviation)  
• A significant protocol required assessment or procedure was not perf ormed per protocol 
requirements  
• Subject received incorrect study medications at any time during the trial   
• Significant departur e from protocol -required dosing  (dosing extravasation)  
• Subject developed criteria that required withdrawal from study  protocol but was not 
withdrawn  
• The sensor was removed prior to measurement of a tGFR  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663265] safety and/or compromise 
the integrity of the clinical trial data.   
 
Subjects who experience a sensor dislodgement, a dosing or device issue or an extravasation  
(which would be considered a major deviation)  will have PK sample collection discontinued and 
the sensor removed, but will be asked to remain in the study for safety follow -up (including dosing 
day safety assessments and the follow -up visit). The event that triggered the discontinuation of PK 
/ fluorescen t data collection will be considered the protocol deviation, however missing PK sample 
collection s will not need t o be documented as individual protocol deviations .  
 
Deviations will be documented at the site and submitted to the IEC (as required) and the sponsor.  
 
10.[ADDRESS_663266] Data Collection  
Fluorescent measurements will be collected directly by [CONTACT_512543]® Transdermal GFR 
Measurement System  and will not appear on any available source documentation  with the 
exception of the tGFR which will be recorded onto the site source document and transcribed into 
the EDC . The MediBeacon® Transdermal GFR Measurement System  will be a closed system . 
11 Records / Retention  
Essential documents are those documents that individually and collectively permit evaluation of 
the study and quality of the data produced .  After completion of the study, all documents and 
data relating to the study will be kept in an orderly manner by [CONTACT_9916] a secure study 
file. All study records  will be available for inspection by [CONTACT_17091] , or a 
regulatory agency .  
 
Investigator files containing all records and reports of the investigation should be retained for a 
minimum of two (2) years  (US) and 5 years (China)  after the completion/ termination of the 
investigational study  or the date that the records are no longer required for purposed of 
supporting a premarket approval application .  The Sponsor will determine with the 
investigational site as to this exact date so that the minimum two-year record retention can be 
accomplished.   Records  may be discarded upon written notification by [CONTACT_1034].  To avoid 
error, the Principal Investigator [INVESTIGATOR_512503] , before the destruction of any 
records and reports pertaining to the study to ensure they no longer need to be retained.  
 
In addition, in accordance with the Clinical Trial  Agreement, the Sponsor should be contact[CONTACT_512544] [INVESTIGATOR_512504].  
 
The following records mu st be maintained in designated s tudy administrative files:  
• Clinical protocol and all amendments  
• Signed Investigator Agreement  
• Independent Ethics Committee Approval Letter(s) documenting review and approval of 
all protocols, amendments, IBs, ICFs, subject materials, etc.   
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 49 of 57 
 • IEC-approved informed consent(s) (including any revisions)  
• Current CV for all Investigators and subinvestigators including evidence of current 
medical licensure  
• Financial Disclo sure Form for all Investigators  
• Site Delegation of Authority Log  
• Correspondence relating to this study  
• Correspondence with the IEC  
• IEC membership list and/or assurance  
• Investigational site authorized study personnel signature l ist and delegation of authority  
• Device Instructions for Use  
• Lab certification, including a set of the lab’s normal range for tests performed  
• EDC Completion Guidelines   
• Subject Screening & Enrolment  Log  
• Site Visit Log (e.g. for Monitor sign -in)  
• Site Training records  
• Investigational Device  and Drug  Accountability Logs  
• Reports (includes Adverse Event reports and final reports from Investigator and Spons or) 
• Copy of all EC approved subject -related materials and/or study advertising materials  
 
The following records must be maintained for each subject enrolled in the study:  
• Signed subject consent forms  
• Electron ic copy of final completed case reports  (to be provided by [CONTACT_512545])  
• Jump drive with subject’s fluorescent data from the TGFR system  
• All lab  work and testing results  
• Record of any complications, adverse events, device problems and/or malfunctions, with 
supporting documentation  
• Procedure reports, progress notes, physician and/or nursing notes, and subject office files  
• Records pertaining to subject deaths  
 
12 Ethics  
12.1 Independent Ethics Committee (IEC) 
Before initiation of the study at each study site, the protocol, all protocol amendments, 
Investigators Brochure, the ICF, the subject information sheet and any other relevant study 
documentation will be submitted to the appropriate IEC.  Written approval of the study and all 
relevant study information must be obtained before the study site can be initiated or the study 
device  is released to the investigator .  Any necessary extensions or renewals of IEC approval 
must be obtained, in particular, for changes to the study such as modification of the protocol, the 
ICF, the written information provided to subjects , and/or other procedures.  
The investigator will report promptly to the IEC any new information that may adversely affect 
the safety of the subjects or the conduct of the study .  The investigator will submit written 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663267] of the Study  
The ICH guidelines  for current GCP (ICH R2, 2016 ), the National Medical Products 
Administration Good Clinical Practice (NMPA GCP) , the Code of Federal Regulations Title 21 
CFR Parts 812, 11, 50, 54 and 56 and ISO [ZIP_CODE]: 2020 (E) Clinical Investigation of Medical 
Devices for Human Subjects – Good Clinical Practice , as well as  the ethical principles defined 
by [CONTACT_512546] , and the requirements of national 
device  and data protection laws and other applicable regulatory requirements will be followed.  
  
12.[ADDRESS_663268] should be 
given every opportunity to ask for clarification of any points he/she does not understand and, if 
necessary, ask for more information .  At the end of the interview, the subject will be given time 
to consider the study, if this is required, or if the subject requests more time .  Subjects and/or 
legal ly authorized represe ntatives will be required to sign and date the ICF .  After signatures are 
obtained, a copy will be provided to the subject, and a signed ICF will be kept and archived by 
[CONTACT_41798]’s study file for possible inspection by [CONTACT_12721], 
the IEC, or sponsor . 
It should be emphasized to the subject that he/she is at liberty to withdraw from the study at any 
time, without penalty or loss of benefits to which the subject is otherwise entitled .  Subjects who 
refuse to give or who withdraw written informed consent should not be included or continue in 
the study.  
12.[ADDRESS_663269] Confidentiality  
All personal data collected and processed for the purposes of this study should be managed by 
[CONTACT_63413]/her staff with adequate precautions to ensure confidentiality of those 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 51 of 57 
 data, in accordance with applicable national and/or local laws and regulations on personal data 
protection.  
Monitors, auditors, and other authorized agents of the sponsor and/or its designee, the ethics 
committees approving this research, and any other applicable regulatory agency(ies), will be 
granted direct access to the study subjects’ original medical records (including electronic medical 
records) for verification of clinical study procedures and/or data, without violating the 
confidentiality of the subjects to the extent permitted by [CONTACT_512547] .  In any 
presentations of the results of this study or in publications, the subjects’ identity will remain 
confidential.  
12.6 Reporting and Publication, Including Archiving  
Publication of all study results in the form of abstracts, manuscript s, presentations, posters, etc. 
will be developed in accordance wi th the Clinical Trial  Agreement.  
  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 52 of 57 
  
 
13 References  
Agarwal R. Ambulatory GFR measurement with cold iothalamate in adults with chronic kidney 
disease. Am J Kidney Dis. 2003 Apr; 41(4): 752 -9. 
 
Endre ZH, Pi[INVESTIGATOR_512505], Walker RJ.  Clearance and beyond: the complementary roles of GFR 
measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol 
2011 301: F697 -F707 . 
 
Erley CM, Bader BD, Berger ED, et al. Plasma clearance of iodine contrast media as a measure 
of glomerular filtration rate in critically ill patients. Crit Care Med. 2001 Aug; 29(8):1544 -50. 
 
Fitzpatrick TB. Soleil et peau [Sun and skin]. Journal de Médecine Esthétique. 1975; 2:33 -34 
 
Kidney Disease Statistics for the [LOCATION_002]. 
http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/index.aspx#[ADDRESS_663270], Feldman HI, Kusek JW, Eggers 
P, Van Lente F, Greene T, Coresh J; CKD -EPI (Chronic Kidney Disease Epi[INVESTIGATOR_10427]). A New Equation to Estimate Glomerular Filtration Rate . Ann Intern Med. 2009 
May 5;150(9):604 -12. 
 
National Institutes of Health Web Site (Bethesda MD, 08 October 2008), “Annual report targets 
chronic kidney disease in the [LOCATION_002],” http://www.nih.gov/news/health/oct2008/niddk -
08.htm  
 
Stevens , LA and Levey,  AS. Measured GFR as a Confirmatory Test for Estimated  GFR . 2009. J. 
Am Soc Nephrol 20: 2305 -2313.  
 
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function --measured and estimated 
glomerular filtration rate. N Engl J Med. 2006 Jun 8;354 (23):[ADDRESS_663271] JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in 
subjects with normal serum creatinine levels: influence of age and body mass index. Am J 
Kidney Dis. 2005 Aug; 46(2): 233 -41. 
 
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-[ADDRESS_663272]  (on areas considered for 
sensor placement).  
 
 
Source: Fitzpatrick, 1975  
 
  

MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 54 of 57 
 15 Appendix B  Clinical Research Sites  
 
Site 
Number  Institution  PI [INVESTIGATOR_512506]  
401 Nucleus Network  George C. Canas, MD  
(Internal medicine / 
nephrology)  
 [ADDRESS_663273], 
MD, FACP, FASN  
(Internal medicine / 
nephrology)  
 [ADDRESS_663274], Chicago, IL [ZIP_CODE]  
 [LOCATION_003]  
403 Carolina Phase I 
Research  Matthew Hong, MD  
(Family medicine)  
 [ADDRESS_663275] & 
304, Raleigh, NC [ZIP_CODE]  
 [LOCATION_003]  
404 Velocity Clinical 
Research  
 Margaret Chang, MD  
(Family medicine)  
 [ADDRESS_663276]., 
Edgewater, FL [ZIP_CODE]  
 [LOCATION_003]  
406 Endeavor Clinical 
Trials, LLC  
 Hernan Alfonso 
Salazar, DO  
(Family medicine)  
 [ADDRESS_663277] Hospi[INVESTIGATOR_512507] -hui Zhao , MD 
(nephrology)  
Yimin Cui 
(Pharmacist)  
 No. [ADDRESS_663278], Beijing, 100034  
 China  
413 Affiliated Hospi[INVESTIGATOR_512508] , MD 
(nephrology)  
 No. 99, Huaihai West Road, Xuzhou 
City, Jiangsu Province, [ZIP_CODE] 29 
 China  
414 Huashan Hospi[INVESTIGATOR_512509] , MD 
(nephrology)  
Jing Zhang  
 No. 12, Wulumugi Middle Road, 
Shanghai, [ADDRESS_663279] China 
Hospi[INVESTIGATOR_512510]  
(nephrology)  
 #[ADDRESS_663280], 
Chengdu, Sichuan Province  
 China  
  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 55 of 57 
  
Investigator Signature [CONTACT_223552]:  A Pi[INVESTIGATOR_22735] , Open Label, Multi -Center,  Safety and Pharmacokinetic 
Study of MB-102 and the Use of the MediBeacon® Transdermal 
GFR Measurement System in  Normal and Renal Compromised 
Subjects for the Evaluation of Kidney Function  
 
Protocol Number:   
100-[ADDRESS_663281] the study as described in 
compliance with this protocol, GCP, the ethical principles defined by [CONTACT_512548] (20 13), applicable regional regulations  and relevant ICH 
guidelines.  
Once the protocol has been approved by [CONTACT_6179], I will not modify this protocol without 
obtaining prior approval of the MediBeacon  Inc. and of the IEC.  I will submit the protocol 
modifications and/or any ICF modifications to MediBeacon  Inc. and IEC, and approval will be 
obtained before any modifications are implemented.  
I understand that all information obtained during the conduct of the study with regard to the 
subjects’ state of health will be regarded as confidential .  No subjects’ names will be disclosed .  
All subjects will be identified by [CONTACT_266148], laboratory samples or source 
documents forwarded to the sponsor .  Clinical information may be reviewed by [CONTACT_190328] .  Agreement must be obtained from the subject before disclosure of 
subject information to a third  party.  
I will oversee all aspects of study conduct  and will only appropriately delegate responsibilities to 
adequately qualified and trained staff. I will oversee the completion of source data collection 
such that all data collected for the study may be substantiated against accurate source medical 
records.  
Information developed in this clinical study may be disclosed by [CONTACT_512518]. to other 
clinical investigators, regulatory agencies, or other health authority or government agencies as 
required.  
   
Investigator Signature   [CONTACT_512549].  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 56 of 57 
 16 Signature [CONTACT_19618]’s Responsible Officer s 
 
 
16.[ADDRESS_663282]. Joseph Pi[INVESTIGATOR_512511].  
[LOCATION_003]  
 
Phone:  +[PHONE_10645]  (Central Time; [LOCATION_002])  
  [ADDRESS_663283]. Louis, MO [ZIP_CODE]  
MediBeacon Inc.  MediBeacon® Transdermal GFR Measurement System  
Protocol No.  100-003 V 4.0 
 
 
20 Sep  2022  CONFIDENTIAL INFORMATION   Page 57 of 57 
 Appendix I  Protocol 100 -003 Supplemental Justifications  
 